Boehringer Ingelheim is to collaborate with UK biotech Autifony Therapeutics to develop an early-stage schizophrenia drug and other compounds. Although central nervous system diseases are a focus ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...

Boehringer Ingelheim Human Pharma head Carinne Brouillon said ... agreement with Sosei Heptares for the development of a new class of therapies for all schizophrenia symptoms. Under the deal, the ...

Prescription digital therapeutics for mental health have the potential to increase patient access to care, but major barriers ...

A comprehensive EU-wide mental health strategy is essential to tackle the region’s growing mental health crisis. Prioritising ...

No individual antipsychotic was associated with better cognitive outcomes than placebo in patients with schizophrenia spectrum disorders (SSD), according to a systematic review and network ...

Tokyo, Japan and Cambridge, UK, 23 October 2024 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) - formerly ...

And, while not all mental health conditions are life-threatening, some of the most prevalent serious mental conditions such as schizophrenia ... Mental Health at Boehringer Ingelheim sat down ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...

Two thirds of people around the world struggle to access mental health support but can we economically afford to continue down this path?